Markets

Roche Launches Global VENTANA BAP1 (SP527) Test To Distinguish Malignant Mesothelioma From Lung, Breast, Stomach Cancers, Expanding Cancer Diagnostic Portfolio

Oct 28, 2026 · 02:26 AM ET· updated 53m ago

The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen.Most patients are diagnosed with

Why It Matters

Roche made a new test that helps doctors tell mesothelioma apart from other cancers. This shows the company is growing its tools for finding the right diagnosis quickly.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RHHBY60.37

+0.39 (+0.65%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.